Physician profile
Hangjun Jang
NPI 1568607919
$22,357.18
in general payments reported to CMS, 2019-2025
53 companies · $2,853 in 2025
The $2,853 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,241 · 2020: $888 · 2021: $3,004 · 2022: $3,207 · 2023: $2,905 · 2024: $3,259 · 2025: $2,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,006 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,005.93 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,556.62 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $1,772.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,362.48 | 2019-2025 | Xifaxan, Trulance, Cycloset |
| Glaxosmithkline, LLC. | $1,328.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $1,251.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,110.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,001.78 | 2021-2025 | |
| Lilly USA, LLC | $806.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $763.25 | 2022-2025 | Rexulti |
| Gilead Sciences, INC. | $684.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $628.70 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $617.61 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $612.16 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $551.77 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $541.89 | 2019-2023 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $476.10 | 2022-2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $442.23 | 2019-2025 | Trintellix |
| Pfizer INC. | $355.70 | 2019-2024 | |
| Allergan, INC. | $334.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $312.95 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $301.93 | 2021-2023 | |
| Axsome Therapeutics, INC. | $295.71 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $263.18 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $253.58 | 2019-2022 | |
| Lundbeck LLC | $237.94 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $232.30 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $228.22 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $225.36 | 2019-2022 | |
| Radius Health, INC. | $207.60 | 2019-2021 | |
| Optinose US, INC. | $205.48 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $158.87 | 2021-2023 | Mitigare, Ryaltris, Kloxxado |
| Vertical Pharmaceuticals, LLC | $144.45 | 2019 | |
| Scilex Pharmaceuticals INC. | $134.29 | 2020-2022 | |
| Esperion Therapeutics, INC. | $111.15 | 2020-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $94.96 | 2022 | |
| Medicomp INC | $83.04 | 2021-2023 | Telepatch Cardiac Monitor |
| Heartflow, INC. | $80.40 | 2024 | |
| Biogen, INC. | $70.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $64.16 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $63.12 | 2019-2021 | |
| Genentech USA, INC. | $60.68 | 2019-2020 | |
| Cvrx, INC. | $50.11 | 2024 | Barostim Neo System |
| Eyevance Pharmaceuticals LLC | $49.09 | 2021 | |
| Intra-Sana Laboratories | $41.86 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Aimmune Therapeutics, INC. | $22.47 | 2025 | Zenpep |
| Almatica Pharma LLC | $22.38 | 2025 | Teriparatide |
| Lexicon Pharmaceuticals, INC. | $21.93 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $21.71 | 2024 | |
| Shionogi INC | $20.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.82 | 2022 | |
| Redhill Biopharma INC. | $20.19 | 2021 | |
| Daiichi Sankyo INC. | $18.70 | 2023 | Injectafer |
| Phadia US INC. | $18.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hangjun Jang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.